drugset / Trial / NCT00464737

The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults.

NCT00464737

Phase 2 Completed 230 enrolled UCB Pharma
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is to investigate the efficacy and safety of rotigotine as compared to placebo in reducing signs and symptoms of fibromyalgia syndrome. The effects of rotigotine on pain, sleep, general activity, mood, and quality of life, and the use of rescue medication to treat pain will be assessed.

Timeline

Start
2007-03
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Rotigotine Unknown 4 mg
Subject Rotigotine Unknown 8 mg

Indications